sglt2 and glp 1 combination GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Efficacy and safety of the

One study author noted, "Understanding the potential side effects of these treatment modalities, though rare, may help individuals and their care teams weigh each treatment's risks and benefits to develop a personalized regimen" [4]

By catalyzing the phosphorylation and degradation of IkB at specific amino acid residues, NFkB can translocate from the cytoplasm to the nucleus and further activate immune mediators such as IL-6 and IL-8 (122)

The medication simultaneously binds GIP (glucose-dependent insulinotropic peptide) and GLP-1 (glucagon-like peptide-1) receptors and activates them

Frontiers, Zeng, Xianfeng, et al